An open-label, Phase II trial of CTP-656 in cystic fibrosis patients.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Ivacaftor deuterated (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 24 Oct 2018 According to a Vertex Pharmaceuticals media release, the company plans to initiate this study in the first half of 2019.
- 19 Jan 2017 New trial record
- 17 Jan 2017 According to Concert Pharmaceuticals media release, topline data from this European study is expected by year-end 2017.